US-based biotechnology firm that develops novel anticancer therapeutics using antibody-drug conjugate (ADC) technology, ImmunoGen (IMGN) has signed a licensing agreement with Novartis, pursuant to which, Novartis has the exclusive right to ...
Tags: Immunogen, Novartis, ADC Technology
Amgen has licensed ImmunoGen's Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics for an undisclosed amount. ImmunoGen president and CEO Daniel Junius said major healthcare companies are interested in developing ...
Tags: anticancer therapeutics, healthcare companies, healthcare, ImmunoGen
Roche Group member, Genentech has received US Food and Drug Administration (FDA) official approval of priority review designation for trastuzumab emtansine Biologics License Application (BLA). Trastuzumab Emtansine is designed to treat ...